# Acute Intermittent Porphyria Market

> Acute Intermittent Porphyria Market Research Report Information: By Diagnosis (Blood, Urine, DNA, Serum), Treatment (Gonadotropin-Releasing Hormone Analogues, Prophylactic Hematin Infusions), End User (Hospitals & Clinics, Research Centers) - Forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.9%
- **2024:** $ 4.61 Billion
- **2025:** $ 4.93 Billion
- **2035:** $ 9.6 Billion
- **Key Players:** Alnylam Pharmaceuticals (US), Pfizer (US), Bristol-Myers Squibb (US), Horizon Therapeutics (IE), Sarepta Therapeutics (US), Amgen (US), Vertex Pharmaceuticals (US), Novartis (CH)

**Report ID:** MRFR/Pharma/3291-HCR · **Pages:** 125 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/acute-intermittent-porphyria-market-4713

---

## Market Summary

## **Acute Intermittent Porphyria Market Overview **

Acute intermittent porphyria market share register 4.61 billion USD in 2024, projected to grow 6.90% CAGR during the forecast period (2024 - 2032). As per MRFR analysis, the acute intermittent porphyria market industry size is expected to grow from 4.35 billion USD in 2023 to 7.34 billion USD by 2032.

The rising frequency of metabolic illnesses, gastrointestinal concerns, urinary tract issues, and health insurance coverage are driving the expansion of the market. Also, the growing elderly population will boost the market expansion.

Acute intermittent porphyria (AIP) is a metabolic condition caused by a genetic mutation. It affects the formation of heme, hemoglobin's oxygen-binding prosthetic group. It is characterized by a lack of the enzyme porphobilinogen deaminase. Acute intermittent porphyria is caused mostly by aberrant urine color, anorexia, sleeplessness, myalgia, and urinary retention. AIP can cause liver cancer (hepatocellular carcinoma) and renal failure in some people. Other symptoms include gastrointestinal problems, urinary tract problems, neurological problems, and psychological problems.

The rising prevalence of lifestyle-related disorders such as obesity is propelling the target market forward. Furthermore, the increased availability of money and fast-expanding government support for R&D will create several potential prospects for the acute intermittent porphyria market throughout the forecast years.

Alnylam Pharmaceuticals (Nasdaq: ALNY), a leader in RNAi therapeutics, announced in November 2019 that GIVLAARI™ (givosiran) injection for subcutaneous use has been approved by the U.S. Food and Drug Administration (FDA) to treat adults with acute hepatic porphyria (AHP). AHP represents a collection of rare genetic disorders, which are usually characterized by severe and life-threatening attacks as well as ongoing symptoms in some patients, depriving them of the possibility of functioning normally and leading their usual life. Chronic neuropathic pain, hypertension, chronic kidney disease, and liver disease are long-term complications of AHP.

Those who took GIVLAARI had significantly lower attack rates compared to those who were hospitalized because of porphyria attacks or required urgent healthcare visits or IV hemin administration at home.

In November 2018, Recordati Rare Diseases Canada Inc., which is a biopharmaceutical company offering orphan treatments to patients with rare diseases, announced the market roll-out of PANHEMATIN®, the first Health Canada-authorized drug used in treating recurrent attacks of acute intermittent porphyria (AIP). Acute intermittent porphyria (AIP) is an uncommon metabolic disorder resulting in reduced heme-producing activities caused by the dysfunction of several enzymes. Most symptoms occur as severe abdominal pain episodes along with many other varied gastrointestinal system abnormalities, cardiovascular events, psychiatric events, or neurological events that may be fatal or progress to irreversible neuronal damage.

**COVID-19 Analysis**

With the rise of the Covid-19 impact, many large-scale businesses and industries suffered, except healthcare and life support products. The lockdown and physical distancing protocols have affected millions of small and big business institutions alike. The acute intermittent porphyria market saw a slight downfall post the pandemic due to the lockdown and physical distancing.

The pandemic has severely hindered the market growth, which has affected the forecast market value significantly. However, the pandemic situation is expected to wear off in the coming years. Hence, the severe intermittent porphyria market will see steady growth in the forecast years.

## **Acute Intermittent Porphyria Market Trends**

**Drivers**

A few factors may drive the growth of the acute intermittent porphyria market share. The rising frequency of metabolic illnesses, gastrointestinal concerns, urinary tract issues, and health insurance coverage are driving the expansion of the market. Also, the growing elderly population will boost the market expansion.

The rising awareness about severe intermittent porphyria and the expansion of the healthcare sector in emerging markets are the primary drivers that fuel the growth of the market. 

**Opportunities**

According to WHO evaluations, neurological diseases account for 4.5 percent -11 percent of all illnesses in poor and high-income countries. This is significantly more than the number of respiratory diseases, gastrointestinal diseases, or malignancies, and the burden is anticipated to grow even more in the future years. This is expected to fuel the acute intermittent porphyria market growth in the forecast years.

**Restraints**

There are a few factors that may hinder the growth of the market value. Some of the factors that may impede the development of the market during the projected period include the availability of pricey treatment and inadequate reimbursement policies in emerging countries of the world. 

**Challenges **

In emerging regions, common knowledge and insufficient access to excellent healthcare are restricting acceptance. The disorder's asymptomatic form creates delays in diagnosis, limiting uptake in the areas and hindering the acute intermittent porphyria market growth.

**Cumulative Growth Analysis**

The acute intermittent porphyria market is anticipated to grow substantially in the years to come. The severe intermittent porphyria treatment market value is expected to grow at a CAGR of about 5.6%. The rising frequency of metabolic illnesses, gastrointestinal concerns, urinary tract issues, and health insurance coverage are driving the expansion of the market. Also, the growing elderly population will boost the market expansion.

**Value Chain Analysis**

Rapid advances in metabolic diseases diagnosis are expected to drive acute hepatic porphyria market growth. Moreover, increasing regulatory clearances to allow potentially life-saving therapeutic techniques is broadening the scope of the market growth for acute intermittent porphyria. APH treatments benefit greatly from the government's strong support for advanced research, which also fuels market growth in the long run. The rising awareness about severe intermittent porphyria and the expansion of the healthcare sector in emerging markets are the primary drivers that fuel the growth of the market. 

## **Acute Intermittent Porphyria Market Segment Insights**

The acute intermittent porphyria market** **is classified into many segments such as diagnosis, treatment, and end-user. Listed below are the severe intermittent porphyria market segments:

### **Acute Intermittent Porphyria Market Regional Insights**

The regional division of the acute intermittent porphyria market analysis comprises North America, Europe, Asia Pacific, and the rest of the world. The Americas rule over the global acute intermittent porphyria treatment market because of well-developed technology, increased patients with inherited metabolic abnormalities, high healthcare spending, and government funding for research and development. Also, the increased R&D efforts and the concentration of significant corporations have fueled market expansion in this area.

Because of government support for R&D and the availability of research money, Europe ranks second in the global severe intermittent porphyria market. This is projected to drive the European market for the foreseeable future. Countries such as Germany and France, for example, are expanding their investments in healthcare.

Because of rapidly increasing healthcare technology, a large patient population, and high healthcare spending, Asia Pacific is the fastest growing acute intermittent porphyria market. Furthermore, the rising demand for innovative treatment approaches in nations such as India and South Korea is expected to make them the world's fastest expanding markets.

Furthermore, rising demand for high-quality medical devices is expected to enhance the adoption of modern equipment, fueling the expansion of the market in the area. On the other hand, blood disorders have become a major issue throughout the Middle East and Africa due to preliminary screening, disease ignorance, and restricted access to treatment.

### **Acute Intermittent Porphyria Key Market players & Competitive Insights**

The acute intermittent porphyria industry is dominated by a few companies that play a vital role in the market growth. These acute intermittent porphyria treatment services companies are called key companies of the market. They contribute to the largest share of the market profit.

The companies account for the market profits by adopting various acute intermittent porphyria market trends such as joint ventures, product launches, company expansions, and procurements.

**Key Companies in the acute intermittent porphyria market include**

Below are the key companies that offer acute intermittent porphyria treatment services in the global market, with the location of their headquarters:

## **Acute Intermittent Porphyria Market Segmentation**

### **Acute Intermittent Porphyria Diagnosis Outlook**

### **Acute Intermittent Porphyria Treatment Outlook**

### **Acute Intermittent Porphyria End-user Outlook**

### **Acute Intermittent Porphyria Regional Outlook**

## Acute Intermittent Porphyria Market Industry Developments

- **Q2 2024: Alnylam Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for GIVLAARI® (givosiran) for Expanded Indication in Acute Intermittent Porphyria** Alnylam Pharmaceuticals received FDA approval for a supplemental new drug application expanding the indication of GIVLAARI® (givosiran) to include additional patient populations with acute intermittent porphyria, marking a significant regulatory milestone for the company.
- **Q1 2024: Recordati Rare Diseases Announces European Commission Approval of Panhematin® for Acute Intermittent Porphyria** Recordati Rare Diseases secured European Commission approval for Panhematin® as a treatment for acute intermittent porphyria, enabling broader access to the therapy across the European Union.
- **Q2 2024: Mitsubishi Tanabe Pharma Launches Phase 3 Clinical Trial of Novel RNAi Therapy for Acute Intermittent Porphyria** Mitsubishi Tanabe Pharma initiated a Phase 3 clinical trial to evaluate the safety and efficacy of its investigational RNA interference (RNAi) therapy for patients with acute intermittent porphyria.
- **Q1 2024: Dicerna Pharmaceuticals Announces Strategic Partnership with Rare Disease Foundation to Advance Acute Intermittent Porphyria Research** Dicerna Pharmaceuticals entered into a strategic partnership with a leading rare disease foundation to support research and development efforts focused on new therapies for acute intermittent porphyria.
- **Q3 2024: Alnylam Pharmaceuticals Appoints New Chief Medical Officer to Lead Rare Disease Portfolio** Alnylam Pharmaceuticals appointed a new Chief Medical Officer to oversee its rare disease portfolio, including the acute intermittent porphyria program, as part of its executive leadership expansion.
- **Q2 2025: Recordati Rare Diseases Opens New Manufacturing Facility for Porphyria Treatments in Europe** Recordati Rare Diseases inaugurated a new manufacturing facility in Europe dedicated to the production of treatments for acute intermittent porphyria, aiming to increase supply and improve distribution efficiency.
- **Q1 2025: Alnylam Pharmaceuticals Announces $150 Million Follow-on Public Offering to Fund Rare Disease Pipeline** Alnylam Pharmaceuticals completed a $150 million follow-on public offering to support the continued development and commercialization of its rare disease pipeline, including therapies for acute intermittent porphyria.
- **Q2 2024: Mitsubishi Tanabe Pharma Receives Orphan Drug Designation from FDA for AIP Therapy** Mitsubishi Tanabe Pharma was granted orphan drug designation by the U.S. FDA for its investigational therapy targeting acute intermittent porphyria, providing regulatory incentives for further development.
- **Q3 2024: Recordati Rare Diseases Signs Distribution Agreement with Major European Specialty Pharmacy for AIP Treatments** Recordati Rare Diseases entered into a distribution agreement with a major European specialty pharmacy to expand access to its acute intermittent porphyria treatments across multiple countries.
- **Q1 2025: Alnylam Pharmaceuticals and Moderna Announce Collaboration to Develop mRNA-based Therapy for Acute Intermittent Porphyria** Alnylam Pharmaceuticals and Moderna announced a collaboration to co-develop an mRNA-based therapy for acute intermittent porphyria, combining Alnylam's rare disease expertise with Moderna's mRNA technology.
- **Q2 2025: Mitsubishi Tanabe Pharma Expands Global Clinical Trial Sites for AIP Therapy to North America and Asia** Mitsubishi Tanabe Pharma expanded its global clinical trial network for its acute intermittent porphyria therapy, adding new sites in North America and Asia to accelerate patient recruitment and data collection.
- **Q2 2024: Dicerna Pharmaceuticals Raises $80 Million in Series C Financing to Advance AIP Drug Candidate** Dicerna Pharmaceuticals secured $80 million in Series C financing to support the clinical development of its lead drug candidate for acute intermittent porphyria.

## Report Overview

This report delivers all the information about the acute intermittent porphyria market size in the forecast period. It also contains different sections of the market analysis to help obtain detailed information such as opportunities, challenges, drivers, Covid-19 analysis, regional analysis, competitive landscape, and others. Moreover, all the information is collected from verified primary and secondary sources to provide the expected market outlook.

## Market Drivers

### Enhanced Diagnostic Techniques

The development of enhanced diagnostic techniques is playing a crucial role in the Acute Intermittent Porphyria Market. Improved methods for diagnosing AIP, such as advanced genetic testing and biomarker identification, are facilitating earlier and more accurate detection of the disease. This advancement is essential, as timely diagnosis can significantly impact patient management and treatment outcomes. The increased accuracy of diagnostic tools is likely to lead to a higher rate of confirmed cases, thereby expanding the patient population in need of treatment. Furthermore, as diagnostic technologies evolve, they may also contribute to the understanding of AIP pathophysiology, potentially leading to new therapeutic targets and strategies.

### Innovative Therapeutic Developments

The Acute Intermittent Porphyria Market is witnessing a surge in innovative therapeutic developments. Recent advancements in [gene therapy](https://www.marketresearchfuture.com/reports/gene-therapy-market-8399) and small molecule drugs are showing promise in managing AIP symptoms and reducing attack frequency. For instance, therapies targeting the heme biosynthesis pathway are under investigation, which could potentially transform treatment paradigms. The introduction of novel therapies not only enhances patient outcomes but also attracts investment and research funding, further propelling market growth. As pharmaceutical companies invest in research and development, the pipeline for new treatments is expanding, indicating a robust future for the market. This innovation is crucial, as existing treatment options may not be effective for all patients, highlighting the need for diverse therapeutic strategies.

### Rising Patient Advocacy and Support Groups

The emergence of patient advocacy and support groups is influencing the Acute Intermittent Porphyria Market positively. These organizations play a vital role in raising awareness about AIP, educating patients and healthcare providers, and advocating for better treatment options. Their efforts are likely to lead to increased recognition of the disease, which could result in more individuals seeking diagnosis and treatment. Additionally, these groups often collaborate with researchers and pharmaceutical companies to promote clinical trials and research initiatives, thereby enhancing the overall landscape of AIP management. As patient voices become more prominent, the market may see a shift towards more patient-centered care approaches, ultimately benefiting those affected by AIP.

### Growing Investment in Rare Disease Research

Investment in research focused on rare diseases, including Acute Intermittent Porphyria Market, is a significant driver for the Acute Intermittent Porphyria Market. Governments and private entities are increasingly recognizing the importance of funding research initiatives aimed at understanding and treating rare conditions. This trend is evidenced by the allocation of substantial grants and resources to AIP research, which could lead to breakthroughs in treatment and management. The financial backing not only supports clinical trials but also fosters collaboration among academic institutions, pharmaceutical companies, and healthcare providers. As a result, the market is likely to benefit from enhanced research output, leading to improved diagnostic tools and therapeutic options for AIP patients.

### Increasing Prevalence of Acute Intermittent Porphyria

The rising incidence of Acute Intermittent Porphyria Market (AIP) is a notable driver for the Acute Intermittent Porphyria Market. Recent estimates suggest that AIP affects approximately 1 in 20,000 individuals, with a higher prevalence in certain populations. This increasing prevalence is likely to lead to a greater demand for diagnostic and therapeutic options, thereby expanding the market. As awareness grows among healthcare professionals and patients, more individuals are being diagnosed, which could further stimulate market growth. The need for specialized care and management of AIP symptoms is becoming increasingly recognized, indicating a potential for new treatment modalities and healthcare services tailored to this condition. Consequently, the market is poised for expansion as healthcare systems adapt to meet the needs of this patient population.

## Future Outlook

The Acute Intermittent Porphyria Market is projected to grow at a 6.9% CAGR from 2025 to 2035, driven by advancements in diagnostics, increased awareness, and novel therapeutic options.

**New opportunities:**

- Development of targeted gene therapies for AIP patients. Expansion of telehealth services for [remote patient monitoring](https://www.marketresearchfuture.com/reports/remote-patient-monitoring-market-10905). Investment in AI-driven diagnostic tools for early detection.

By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in rare disease management.

## Segment Insights

### By Diagnosis: Urine Test (Largest) vs. DNA Test (Fastest-Growing)

In the Acute Intermittent Porphyria Market, the diagnosis segment showcases significant diversity, with various tests contributing to acute intermittent porphyria market share. The Urine Test emerges as the largest segment, widely utilized due to its effectiveness in detecting porphyrins that assist in diagnosing the condition. Following the Urine Test are Blood Tests and Serum Tests, which also hold notable shares as traditional methods of diagnosis. DNA Tests, while smaller in percentage, are gaining traction thanks to advances in genetic testing, providing more accurate insights into inherited forms of the disorder.

Urine Test (Dominant) vs. DNA Test (Emerging)

The Urine Test is a dominant player within the diagnosis segment of the Acute Intermittent Porphyria Market, primarily favored for its reliability in detecting elevated porphyrin levels. This test has established itself as a first-line diagnostic tool due to its non-invasive nature and ability to provide quick results. In contrast, the DNA Test is emerging as a potent market force, driven by technological advancements in genetic testing, contributing to evolving acute intermittent porphyria market trends.

### By Treatment: Prophylactic Hematin Infusions (Largest) vs. Gonadotropin-Releasing Hormone Analogues (Fastest-Growing)

In the Acute Intermittent Porphyria Market, the treatment segment exhibits a diverse landscape characterized by three major categories: Prophylactic Hematin Infusions, Gonadotropin-Releasing Hormone Analogues, and Others. Prophylactic Hematin Infusions hold the largest share due to their established efficacy and long-standing use in managing acute episodes. In contrast, Gonadotropin-Releasing Hormone Analogues are quickly gaining traction, reflecting evolving acute intermittent porphyria treatment market trends among healthcare providers and patients alike. The growth of the treatment segment is predominantly driven by advancements in therapeutic modalities and increasing awareness about Acute Intermittent Porphyria Market, further strengthening acute intermittent porphyria treatment market insight. Gonadotropin-Releasing Hormone Analogues are emerging as a promising alternative, particularly as patients seek options that minimize acute episodes while enhancing overall quality of life. This dual focus on established treatments and innovative therapies propels the market forward, underscoring the dynamic nature of this segment.

Prophylactic Hematin Infusions (Dominant) vs. Gonadotropin-Releasing Hormone Analogues (Emerging)

Prophylactic Hematin Infusions currently dominate the Acute Intermittent Porphyria Market treatment landscape due to their historical usage and proven effectiveness in preventing symptoms. These infusions are essential for patients experiencing recurrent attacks and are supported by a wealth of clinical experience. On the other hand, Gonadotropin-Releasing Hormone Analogues represent an emerging approach, focusing on hormonal regulation and showing promise in alleviating acute crises. While Hematin infusions offer immediate relief, the analogues are gaining recognition for their potential long-term benefits, capturing the interest of both providers and patients who are keen on exploring novel treatment avenues. Together, these treatments reflect the evolving strategies in managing Acute Intermittent Porphyria Market, demonstrating both the established norms and the innovative future.

### By End-user: Hospitals & Clinics (Largest) vs. Medical Research Centers (Fastest-Growing)

In the Acute Intermittent Porphyria Market, the distribution among end-user segments reveals that hospitals and clinics hold the largest share. These facilities play a critical role in diagnosing and treating acute intermittent porphyria, making them integral to the patient care continuum. On the other hand, medical research centers are emerging as a significant player, highlighting their importance in advancing therapies and treatment methodologies, which is reshaping the market dynamics.

Hospitals & Clinics (Dominant) vs. Medical Research Centers (Emerging)

Hospitals and clinics dominate the Acute Intermittent Porphyria Market due to their essential functions in patient management and direct care. They have established infrastructure, trained personnel, and treatment protocols that favor their continued supremacy in service provision. Conversely, medical research centers are becoming vital players as they focus on clinical trials and innovative research, generating breakthroughs that drive therapy advancements. The demand for specialized research and new treatment modalities positions these centers as an emerging and critical segment that will shape future care approaches in acute intermittent porphyria.

## Regional Market Share Analysis

The regional division of the acute intermittent porphyria market analysis comprises North America, Europe, Asia Pacific, and the rest of the world. The Americas rule over the global acute intermittent porphyria treatment market because of well-developed technology, increased patients with inherited metabolic abnormalities, high healthcare spending, and government funding for research and development. Also, the increased R&D efforts and the concentration of significant corporations have fueled market expansion in this area.

Because of government support for R&D and the availability of research money, Europe ranks second in the global severe intermittent porphyria market. This is projected to drive the European market for the foreseeable future. Countries such as Germany and France, for example, are expanding their investments in healthcare.

Because of rapidly increasing healthcare technology, a large patient population, and high healthcare spending, Asia Pacific is the fastest growing acute intermittent porphyria market. Furthermore, the rising demand for innovative treatment approaches in nations such as India and South Korea is expected to make them the world's fastest expanding markets.

Furthermore, rising demand for high-quality medical devices is expected to enhance the adoption of modern equipment, fueling the expansion of the market in the area. On the other hand, blood disorders have become a major issue throughout the Middle East and Africa due to preliminary screening, disease ignorance, and restricted access to treatment.

## Competitive Benchmarking

The acute intermittent porphyria industry is dominated by a few companies that play a vital role in the market growth. These acute intermittent porphyria treatment services companies are called key companies of the market. They contribute to the largest share of the market profit.The companies account for the market profits by adopting various acute intermittent porphyria market trends such as joint ventures, product launches, company expansions, and procurements.

## Recent News & Developments

- **Q2 2024: Alnylam Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for GIVLAARI® (givosiran) for Expanded Indication in Acute Intermittent Porphyria Market** Alnylam Pharmaceuticals received FDA approval for a supplemental new drug application expanding the indication of GIVLAARI® (givosiran) to include additional patient populations with acute intermittent porphyria, marking a significant regulatory milestone for the company.
- **Q1 2024: Recordati Rare Diseases Announces European Commission Approval of Panhematin® for Acute Intermittent Porphyria Market** Recordati Rare Diseases secured European Commission approval for Panhematin® as a treatment for acute intermittent porphyria, enabling broader access to the therapy across the European Union.
- **Q2 2024: Mitsubishi Tanabe Pharma Launches Phase 3 Clinical Trial of Novel RNAi Therapy for Acute Intermittent Porphyria Market** Mitsubishi Tanabe Pharma initiated a Phase 3 clinical trial to evaluate the safety and efficacy of its investigational RNA interference (RNAi) therapy for patients with acute intermittent porphyria.
- **Q1 2024: Dicerna Pharmaceuticals Announces Strategic Partnership with Rare Disease Foundation to Advance Acute Intermittent Porphyria Market Research** Dicerna Pharmaceuticals entered into a strategic partnership with a leading rare disease foundation to support research and development efforts focused on new therapies for acute intermittent porphyria.
- **Q3 2024: Alnylam Pharmaceuticals Appoints New Chief Medical Officer to Lead Rare Disease Portfolio** Alnylam Pharmaceuticals appointed a new Chief Medical Officer to oversee its rare disease portfolio, including the acute intermittent porphyria program, as part of its executive leadership expansion.
- **Q2 2025: Recordati Rare Diseases Opens New Manufacturing Facility for Porphyria Treatments in Europe** Recordati Rare Diseases inaugurated a new manufacturing facility in Europe dedicated to the production of treatments for acute intermittent porphyria, aiming to increase supply and improve distribution efficiency.
- **Q1 2025: Alnylam Pharmaceuticals Announces $150 Million Follow-on Public Offering to Fund Rare Disease Pipeline** Alnylam Pharmaceuticals completed a $150 million follow-on public offering to support the continued development and commercialization of its rare disease pipeline, including therapies for acute intermittent porphyria.
- **Q2 2024: Mitsubishi Tanabe Pharma Receives Orphan Drug Designation from FDA for AIP Therapy** Mitsubishi Tanabe Pharma was granted orphan drug designation by the U.S. FDA for its investigational therapy targeting acute intermittent porphyria, providing regulatory incentives for further development.
- **Q3 2024: Recordati Rare Diseases Signs Distribution Agreement with Major European Specialty Pharmacy for AIP Treatments** Recordati Rare Diseases entered into a distribution agreement with a major European specialty pharmacy to expand access to its acute intermittent porphyria treatments across multiple countries.
- **Q1 2025: Alnylam Pharmaceuticals and Moderna Announce Collaboration to Develop mRNA-based Therapy for Acute Intermittent Porphyria Market** Alnylam Pharmaceuticals and Moderna announced a collaboration to co-develop an mRNA-based therapy for acute intermittent porphyria, combining Alnylam's rare disease expertise with Moderna's mRNA technology.
- **Q2 2025: Mitsubishi Tanabe Pharma Expands Global Clinical Trial Sites for AIP Therapy to North America and Asia** Mitsubishi Tanabe Pharma expanded its global clinical trial network for its acute intermittent porphyria therapy, adding new sites in North America and Asia to accelerate patient recruitment and data collection.
- **Q2 2024: Dicerna Pharmaceuticals Raises $80 Million in Series C Financing to Advance AIP Drug Candidate** Dicerna Pharmaceuticals secured $80 million in Series C financing to support the clinical development of its lead drug candidate for acute intermittent porphyria.

## Report Scope

| MARKET SIZE 2024 | 4.61(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 4.928(USD Billion) |
| MARKET SIZE 2035 | 9.604(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.9% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Alnylam Pharmaceuticals (US), Pfizer (US), Bristol-Myers Squibb (US), Horizon Therapeutics (IE), Sarepta Therapeutics (US), Amgen (US), Vertex Pharmaceuticals (US), Novartis (CH) |
| Segments Covered | Diagnosis |
| Key Market Opportunities | Advancements in gene therapy may enhance treatment options in the Acute Intermittent Porphyria Market. |
| Key Market Dynamics | Rising demand for targeted therapies drives innovation and competition in the Acute Intermittent Porphyria Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation for Acute Intermittent Porphyria by 2035?**
A: The projected market valuation for Acute Intermittent Porphyria is expected to reach 9.604 USD Billion by 2035.

**Q: What was the market valuation for Acute Intermittent Porphyria in 2024?**
A: The market valuation for Acute Intermittent Porphyria was 4.61 USD Billion in 2024.

**Q: What is the expected CAGR for the Acute Intermittent Porphyria Market from 2025 to 2035?**
A: The expected CAGR for the Acute Intermittent Porphyria Market during the forecast period 2025 - 2035 is 6.9%.

**Q: Which companies are key players in the Acute Intermittent Porphyria Market?**
A: Key players in the Acute Intermittent Porphyria Market include Alnylam Pharmaceuticals, Pfizer, Bristol-Myers Squibb, Horizon Therapeutics, Sarepta Therapeutics, Amgen, Vertex Pharmaceuticals, and Novartis.

**Q: What are the main diagnostic segments in the Acute Intermittent Porphyria Market?**
A: The main diagnostic segments include Urine Test, Blood Test, Serum Test, DNA Test, and Others, with valuations ranging from 0.46 to 2.35 USD Billion.

**Q: What treatment options are available for Acute Intermittent Porphyria?**
A: Treatment options include Prophylactic Hematin Infusions, Gonadotropin-Releasing Hormone Analogues, and Others, with market values between 1.0 and 4.404 USD Billion.

**Q: What are the primary end-user segments for Acute Intermittent Porphyria treatments?**
A: Primary end-user segments include Hospitals & Clinics, Medical Research Centers, and Others, with valuations from 1.15 to 3.84 USD Billion.

**Q: How does the market for Blood Tests compare to other diagnostic methods?**
A: The Blood Test segment is projected to grow from 1.15 USD Billion to 2.35 USD Billion, indicating a robust demand compared to other diagnostic methods.

**Q: What is the growth potential for the Acute Intermittent Porphyria Market in the coming years?**
A: The market appears poised for growth, with a projected increase to 9.604 USD Billion by 2035, driven by advancements in treatment and diagnosis.

**Q: How do the treatment segment valuations reflect the market dynamics for Acute Intermittent Porphyria?**
A: The treatment segment valuations, particularly for Prophylactic Hematin Infusions, suggest a strong focus on effective management strategies, with values ranging from 1.5 to 3.2 USD Billion.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/acute-intermittent-porphyria-market-4713*